The recent Phase III failure of H. Lundbeck AS' investigational Alzheimer's candidate idalopirdine thrusts a spotlight on the difficulties of breaking into the field of treating the chronic neurodegenerative disease.
Idalopirdine, designed to treat mild to moderate Alzheimer's disease demonstrated a weak efficacy profile, failed to meet the primary endpoint...







